Shuttle Pharmaceuticals Reports Q1 2026 Financial Results with $2.2M Net Loss

Shuttle Pharmaceuticals Holdings, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $2.2 million, a decrease from a net loss of $3.1 million in the same period last year. The company did not generate any revenue during the quarter, consistent with the previous year. Total operating expenses decreased by 25% to $2.2 million, down from $3.0 million in the first quarter of 2025. This reduction was primarily driven by a significant decline in research and development expenses, which fell by 83% to $267,240, largely due to decreased subcontractor costs and a reduction in R&D personnel expenses.

In terms of financial position, Shuttle Pharmaceuticals reported total current assets of $2.5 million as of March 31, 2026, a substantial increase from $502,911 at the end of 2025. This increase was primarily attributed to a successful public offering in March 2026, which raised approximately $3.5 million in gross proceeds. Current liabilities also rose slightly to $8.3 million, resulting in a working capital deficit of $5.8 million, an improvement from a deficit of $7.5 million at the end of the previous year. The company’s cash and cash equivalents stood at $1.1 million, down from $4.5 million a year earlier.

Strategically, Shuttle Pharmaceuticals has made significant moves, including the acquisition of Molecule.ai, an AI-driven platform for drug discovery, in November 2025. This acquisition is expected to enhance the company's capabilities in molecular modeling and predictive analytics, which are critical for its drug development initiatives. The company has also wound down its clinical trials for Ropidoxuridine, reallocating resources towards the commercialization of the Molecule.ai platform.

Operationally, the company has seen changes in its employee headcount and organizational structure, particularly following the retirement of its Chief Scientific Officer and the resignation of other key personnel. The company’s total stockholders’ equity increased to $3.3 million as of March 31, 2026, up from $2.3 million at the end of 2025, reflecting the impact of recent equity financing activities. However, the company continues to face challenges, including a working capital deficit and the need for additional financing to support ongoing operations and future growth.

Looking ahead, Shuttle Pharmaceuticals has expressed concerns regarding its ability to continue as a going concern, emphasizing the need for further equity or debt financing to sustain operations and fund its strategic initiatives. The company plans to utilize proceeds from its recent public offering for marketing efforts and general corporate purposes, while also seeking to enhance its operational capabilities through the integration of the Molecule.ai platform.